Moderna、默克公司发布mRNA癌症疫苗的有希望的数据

2026-06-02 04:53

Moderna (MRNA) and Merck (MRK) said that the experimental cancer vaccine intismeran autogene plus Keytruda (pembrolizumab) led to a 49% decline in the risk of recurrence or death, and a 50% reduction in the risk of distant metastasis, compared to Keytruda alone, or death in patients with late-stage melanoma.
The data is based on a median five-year follow-up of the phase 2 KEYNOTE-942/mRNA-4157-P201.
Overall survival, an exploratory endpoint, also showed a positive trend.
Enrolled patients had high-risk stage III/IV melanoma.
Intismeran autogene, known as an mRNA-individualized neoantigen therapy, is also under investigation by the two companies for other tumor types, including non-small cell lung cancer, bladder cancer, and renal cell carcinoma.

More on Moderna, Merck